User menu

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Bibliographic reference Cooper, Cyrus ; Bardin, Thomas ; Brandi, Maria-Luisa ; Cacoub, Patrice ; Caminis, John ; et. al. Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). In: Aging Clinical and Experimental Research (Online), Vol. 28, no.1, p. 1-16 (2016)
Permanent URL http://hdl.handle.net/2078.1/171359
  1. Baltimore David, Our genome unveiled, 10.1038/35057267
  2. Boers Maarten, Understanding the window of opportunity concept in early rheumatoid arthritis, 10.1002/art.11156
  3. Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Porter Duncan, Kincaid Wilma, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, 10.1016/s0140-6736(04)16676-2
  4. Bakker MF, Jacobs JW, Verstappen SM et al (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. doi: 10.1136/ard.2007.078360
  5. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet. doi: 10.1016/S0140-6736(09)60008-8
  6. S. Saffar Arash, Ashdown Heather, S. Gounni Abdelilah, The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival, 10.2174/138945011794751555
  7. Ytterberg AJ, Joshua V, Reynisdottir G et al (2014) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204912
  8. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med. doi: 10.1056/NEJMra1004965
  9. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med. doi: 10.1056/NEJMra0707449
  10. Jonsson Helena, Allen Paul, Peng Stanford L, Inflammatory arthritis requires Foxo3a to prevent Fas ligand–induced neutrophil apoptosis, 10.1038/nm1248
  11. Turrel-Davin F, Tournadre A, Pachot A et al (2010) FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis. doi: 10.1136/ard.2009
  12. Westwood O. M. R., Nelson P. N., Hay F. C., Rheumatoid factors: what's new?, 10.1093/rheumatology/kei228
  13. Zendman A. J. W., van Venrooij W. J., Pruijn G. J. M., Use and significance of anti-CCP autoantibodies in rheumatoid arthritis, 10.1093/rheumatology/kei111
  14. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. doi: 10.1002/art.24390
  15. Kleyer A, Finzel S, Rech J et al (2013) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-202958
  16. Crowson CS, Rahman MU, Matteson EL (2009) Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. doi: 10.3899/jrheum.081188
  17. Hensvold AH, Magnusson PK, Joshua V et al (2015) Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-203947
  18. Wolfe Frederick, Mitchell Donald M., Sibley John T., Fries James F., Bloch Daniel A., Williams Catherine A., Spitz Patricia W., Haga May, Kleinheksel Sue M., Cathey Mary Ann, The mortality of rheumatoid arthritis, 10.1002/art.1780370408
  19. Boyer Jean-Frédéric, Gourraud Pierre-Antoine, Cantagrel Alain, Davignon Jean-Luc, Constantin Arnaud, Traditional cardiovascular risk factors in rheumatoid arthritis: A meta-analysis, 10.1016/j.jbspin.2010.07.016
  20. Wolfe F (2000) The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 27(3):630–637
  21. Dessein Patrick H., Joffe Barry I., Insulin resistance and impaired beta cell function in rheumatoid arthritis, 10.1002/art.22053
  22. Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). doi: 10.1093/rheumatology/kes243
  23. Stavropoulos-Kalinoglou A., Metsios G. S., Koutedakis Y., Kitas G. D., Obesity in rheumatoid arthritis, 10.1093/rheumatology/keq266
  24. Dougados Maxime, Soubrier Martin, Antunez Anna, Balint Peter, Balsa Alejandro, Buch Maya H, Casado Gustavo, Detert Jacqueline, El-zorkany Bassel, Emery Paul, Hajjaj-Hassouni Najia, Harigai Masayoshi, Luo Shue-Fen, Kurucz Reka, Maciel Gabriel, Mola Emilio Martin, Montecucco Carlo Maurizio, McInnes Iain, Radner Helga, Smolen Josef S, Song Yeong-Wook, Vonkeman Harald Erwin, Winthrop Kevin, Kay Jonathan, Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), 10.1136/annrheumdis-2013-204223
  25. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24(3):445–451
  26. Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30(6):1196–1202
  27. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A, Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study, 10.1080/03009740410005845
  28. Peters MJ, van Halm VP, Voskuyl AE et al (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. doi: 10.1002/art.24836
  29. Avina-Zubieta JA, Thomas J, Sadatsafavi M et al (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-20072
  30. Krishnan E., Declines in Mortality From Acute Myocardial Infarction in Successive Incidence and Birth Cohorts of Patients With Rheumatoid Arthritis, 10.1161/01.cir.0000142864.83780.81
  31. Meune C, Touze E, Trinquart L et al (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). doi: 10.1093/rheumatology/kep252
  32. Jüni Peter, Nartey Linda, Reichenbach Stephan, Sterchi Rebekka, Dieppe Paul A, Egger Matthias, Risk of cardiovascular events and rofecoxib: cumulative meta-analysis, 10.1016/s0140-6736(04)17514-4
  33. Nissen Steven E., Wolski Kathy, Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, 10.1056/nejmoa072761
  34. Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. doi: 10.1136/bmj.c7086
  35. Wellen K. E., Inflammation, stress, and diabetes, 10.1172/jci200525102
  36. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. doi: 10.1038/nature07202
  37. Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. doi: 10.1136/ard.2009.115717
  38. Curtis JR, John A, Baser O (2012) Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). doi: 10.1002/acr.21693
  39. Toms TE, Panoulas VF, Smith JP et al (2011) Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann Rheum Dis. doi: 10.1136/ard.2010.144634
  40. del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44(12):2737–2745
  41. Turesson C, McClelland R L, Christianson T J H, Matteson E L, Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis, 10.1136/ard.2006.052506
  42. Hot A, Lenief V, Miossec P (2012) Combination of IL-17 and TNFalpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-200468
  43. Hot A, Lavocat F, Lenief V et al (2013) Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-201887
  44. McCarey David W, McInnes Iain B, Madhok Rajan, Hampson Rosie, Scherbakova Olga, Ford Ian, Capell Hilary A, Sattar Naveed, Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial, 10.1016/s0140-6736(04)16449-0
  45. Young SP, Kapoor SR, Viant MR et al (2013) The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. doi: 10.1002/art.38021
  46. Park Yong-Beom, Choi Hyon K, Kim Min-Young, Lee Won-Ki, Song Jungsik, Kim Dong-Kee, Lee Soo-Kon, Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study, 10.1016/s0002-9343(02)01186-5
  47. Nadareishvili Z, Michaud K, Hallenbeck JM et al (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case–control study. Arthritis Rheum. doi: 10.1002/art.23935
  48. Doran Michele F., Crowson Cynthia S., Pond Gregory R., O'Fallon W. Michael, Gabriel Sherine E., Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study, 10.1002/art.10524
  49. Toh ML, Kawashima M, Hot A et al (2010) Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis. doi: 10.1136/ard.2009.111757
  50. Felson David T., Anderson Jennifer J., Meenan Robert F., The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses, 10.1002/art.1780331001
  51. O'Dell James R., Haire Claire E., Erikson Nils, Drymalski Walter, Palmer William, Eckhoff P. James, Garwood Vernon, Maloley Pierre, Klassen Lynell W., Wees Steven, Klein Harry, Moore Gerald F., Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications, 10.1056/nejm199605163342002
  52. Boers Maarten, Verhoeven Arco C, Markusse Harry M, van de Laar Mart AFJ, Westhovens Rene, van Denderen J Christiaan, van Zeben Derkjen, Dijkmans Ben AC, Peeters Andre J, Jacobs Piet, van den Brink Hans R, Schouten Hubert JA, van der Heijde Désirée MFM, Boonen Annelies, van der Linden Sjef, Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis, 10.1016/s0140-6736(97)01300-7
  53. Möttönen Timo, Hannonen Pekka, Leirisalo-Repo Marjatta, Nissilä Martti, Kautiainen Hannu, Korpela Markku, Laasonen Leena, Julkunen Heikki, Luukkainen Reijo, Vuori Kaisa, Paimela Leena, Blåfield Harri, Hakala Markku, Ilva Kirsti, Yli-Kerttula Urpo, Puolakka Kari, Järvinen Pentti, Hakola Mikko, Piirainen Heikki, Ahonen Jari, Pälvimäki Ilppo, Forsberg Sinikka, Koota Kalevi, Friman Claes, Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, 10.1016/s0140-6736(98)08513-4
  54. Svensson Björn, Boonen Annelies, Albertsson Kristina, van der Heijde Désirée, Keller Catharina, Hafström Ingiäld, , Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial, 10.1002/art.21298
  55. Goekoop-Ruiterman Y. P. M., De Vries-Bouwstra J. K., Allaart C. F., Van Zeben D., Kerstens P. J. S. M., Hazes J. M. W., Zwinderman A. H., Ronday H. K., Han K. H., Westedt M. L., Gerards A. H., Van Groenendael J. H. L. M., Lems W. F., Van Krugten M. V., Breedveld F. C., Dijkmans B. A. C., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial, 10.1002/art.21405
  56. Bakker Marije F., Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis : A Randomized Trial, 10.7326/0003-4819-156-5-201203060-00004
  57. Vermeer M, Kuper HH, Hoekstra M et al (2011) Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. doi: 10.1002/art.30494
  58. Heimans L, Wevers-de Boer KV, Visser K et al (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-203243
  59. den Uyl D, Ter Wee M, Boers M et al (2013) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-202818
  60. Kirwan JR, Bijlsma JW, Boers M et al (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1:CD006356
  61. Gorter SL, Bijlsma JW, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. doi: 10.1136/ard.2009.127332
  62. Knevel R, Schoels M, Huizinga TW et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. doi: 10.1136/ard.2009.126748
  63. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. doi: 10.1136/ard.2009.123919
  64. Smolen JS, Landewe R, Breedveld FC et al (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204573
  65. Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204588
  66. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). doi: 10.1002/acr.21641
  67. Curtis Jeffrey R., Westfall Andrew O., Allison Jeroan, Bijlsma Johannes W., Freeman Allison, George Varghese, Kovac Stacey H., Spettell Claire M., Saag Kenneth G., Population-based assessment of adverse events associated with long-term glucocorticoid use, 10.1002/art.21984
  68. van der Goes MC, Jacobs JW, Boers M et al (2010) Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. doi: 10.1136/ard.2009.114579
  69. Saag KG (2012) Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. Bull NYU Hosp Jt Dis 70(Suppl 1):21–25
  70. Santiago T, da Silva JA (2014) Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. Ann N Y Acad Sci. doi: 10.1111/nyas.12428
  71. Saag Kenneth G., Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence, 10.1016/s0002-9343(97)90006-1
  72. Van Staa T. P., Leufkens H. G. M., Abenhaim L., Zhang B., Cooper C., Use of Oral Corticosteroids and Risk of Fractures, 10.1359/jbmr.2000.15.6.993
  73. van Staa T. P., Leufkens H. G. M., Abenhaim L., Zhang B., Cooper C., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, 10.1093/rheumatology/39.12.1383
  74. Da Silva J A P, Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data, 10.1136/ard.2005.038638
  75. Vestergaard P., Olsen M. L., Paaske Johnsen S., Rejnmark L., Toft Sorensen H., Mosekilde L., Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark, 10.1046/j.1365-2796.2003.01219.x
  76. Van Staa T. P., Laan R. F., Barton I. P., Cohen S., Reid D. M., Cooper C., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, 10.1002/art.11283
  77. Kanis John A, Johansson Helena, Oden Anders, Johnell Olof, de Laet Chris, Melton L Joseph, Tenenhouse Alan, Reeve Jonathan, Silman Alan J, Pols Huibert AP, Eisman John A, McCloskey Eugene V, Mellstrom Dan, A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk, 10.1359/jbmr.040134
  78. Manning LI, Briggs AM, van Doornum DS et al (2013) Glucocorticoid-induced bone loss is associated with abnormal intravertebral areal bone mineral density distribution. Int J Endocrinol. doi: 10.1155/2013/768579
  79. Carbonare L. Dalle, Arlot M. E., Chavassieux P. M., Roux J. P., Portero N. R., Meunier P. J., Comparison of Trabecular Bone Microarchitecture and Remodeling in Glucocorticoid-Induced and Postmenopausal Osteoporosis, 10.1359/jbmr.2001.16.1.97
  80. Sambrook P N, Osteocyte viability with glucocorticoid treatment: relation to histomorphometry, 10.1136/ard.2003.008839
  81. Aeberli D, Schett G (2013) Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy. Arthritis Res Ther. doi: 10.1186/ar4180
  82. Harvey NC, Gluer CC, Binkley N et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. doi: 10.1016/j.bone.2015.05.016
  83. Lems W. F., Jacobs J. W. G., Van Rijn H. J. M., Bijlsma J. W. J., Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers, 10.1007/bf02207675
  84. Ton Francine N, Gunawardene Samantha C, Lee Hang, Neer Robert M, Effects of Low-Dose Prednisone on Bone Metabolism, 10.1359/jbmr.041125
  85. Chan Michael H.M., Chan Paul K.S., Griffith James F., Chan Iris H.S., Lit Lydia C.W., Wong C.K., Antonio Gregory E., Liu Ester Y.M., Hui David S.C., Suen Michael W.M, Ahuja Anil T., Y. Sung Joseph J., K. Lam Christopher W., Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy, 10.1080/00313020600696231
  86. Kusumbe AP, Ramasamy SK, Adams RH (2014) Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. doi: 10.1038/nature13145
  87. Ramasamy SK, Kusumbe AP, Wang L et al (2014) Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. doi: 10.1038/nature13146
  88. van Staa T.P., Use of oral corticosteroids in the United Kingdom, 10.1093/qjmed/93.2.105
  89. van Staa T. P., Abenhaim L., Cooper C., Zhang B., Leufkens H. G. M., Public health impact of adverse bone effects of oral corticosteroids, 10.1046/j.0306-5251.2001.bjcp.1385.x
  90. Saag Kenneth G., Emkey Ronald, Schnitzer Thomas J., Brown Jacques P., Hawkins Federico, Goemaere Stefan, Thamsborg Gorm, Liberman Uri A., Delmas Pierre D., Malice Marie-Pierre, Czachur Michelle, Daifotis Anastasia G., Lane Nancy, Correa-Rotter Ricardo, Yanover Melissa, Westhovens Rene, Epstein Sol, Adachi Jonathan D., Poubelle Patrice, Melo-Gomes Jose, Rodriguez-Portales Jose A., Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, 10.1056/nejm199807303390502
  91. Cohen Stanley, Levy Robert M., Keller Michael, Boling Eugene, Emkey Ronald D., Greenwald Maria, Zizic Thomas M., Wallach Stanley, Sewell Kathryn L., Lukert Barbara P., Axelrod Douglas W., Chines Arkadi A., Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k
  92. Devogelaer Jean-Pierre, Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach, 10.1016/j.rdc.2006.09.001
  93. van der Goes MC, Jacobs JW, Jurgens MS et al (2013) Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. doi: 10.1007/s00198-012-2073-z
  94. Homik J, Cranney A, Shea B et al (2000) Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2:D001347
  95. Lems WF, Saag K (2015) Bisphosphonates and glucocorticoid-induced osteoporosis: cons. Endocrine. doi: 10.1007/s12020-015-0639-1
  96. Silverman S, Curtis J, Saag K et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. doi: 10.1007/s00198-014-2883-2
  97. Souverein P C, Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study, 10.1136/hrt.2003.020180
  98. Ruyssen-Witrand A, Fautrel B, Saraux A et al (2011) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. doi: 10.1016/j.jbspin.2010.02.040
  99. El-Shaboury A. H., Hayes T. M., Hyperlipidaemia in Asthmatic Patients Receiving Long-term Steroid Therapy, 10.1136/bmj.2.5858.85
  100. Panthakalam S, Bhatnagar D, Klimiuk P, The Prevalence and Management of Hyperglycaemia in Patients with Rheumatoid Arthritis on Corticosteroid Therapy, 10.1177/003693300404900407
  101. Fraser R., Ingram M. C., Anderson N. H., Morrison C., Davies E., Connell J. M. C., Cortisol Effects on Body Mass, Blood Pressure, and Cholesterol in the General Population, 10.1161/01.hyp.33.6.1364
  102. Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case–control analysis. Arthritis Rheum. doi: 10.1002/art.23811
  103. Davis John M., Maradit Kremers Hilal, Crowson Cynthia S., Nicola Paulo J., Ballman Karla V., Therneau Terry M., Roger Véronique L., Gabriel Sherine E., Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study, 10.1002/art.22418
  104. Panoulas V. F., Douglas K. M. J., Stavropoulos-Kalinoglou A., Metsios G. S., Nightingale P., Kita M. D., Elisaf M. S., Kitas G. D., Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis, 10.1093/rheumatology/kem311
  105. Johannesdottir SA, Horvath-Puho E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case–control study. JAMA Intern Med. doi: 10.1001/jamainternmed.2013.122
  106. Cutolo M, Seriolo B, Pizzorni C et al (2008) Use of glucocorticoids and risk of infections. Autoimmun Rev. doi: 10.1016/j.autrev.2008.07.010
  107. Dixon WG, Kezouh A, Bernatsky S et al (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis. doi: 10.1136/ard.2010.144741
  108. Dixon WG, Abrahamowicz M, Beauchamp ME et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-200702
  109. Sihvonen S, Korpela M, Mustonen J et al (2006) Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 33(9):1740–1746
  110. Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. doi: 10.1186/ar3453
  111. Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. doi: 10.1016/S0140-6736(14)61704-9
  112. Silverman MN, Sternberg EM (2008) Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation. doi: 10.1159/000135620
  113. Kadmiel M, Cidlowski JA (2013) Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. doi: 10.1016/j.tips.2013.07.003
  114. Clore JN, Thurby-Hay L (2009) Glucocorticoid-induced hyperglycemia. Endocr Pract. doi: 10.4158/EP08331.RAR
  115. Angelopoulos TP, Tentolouris NK, Bertsias GK et al (2014) Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol 32(1):126–130
  116. Iwamoto Takuya, Kagawa Yoshiyuki, Naito Yutaka, Kuzuhara Shigeki, Kojima Michio, Steroid-Induced Diabetes Mellitus and Related Risk Factors in Patients with Neurologic Diseases, 10.1592/phco.24.5.508.33355
  117. Hoes JN, van der Goes MC, van Raalte DH et al (2011) Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. doi: 10.1136/ard.2011.151464
  118. den Uyl D, van Raalte DH, Nurmohamed MT et al (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. doi: 10.1002/art.3337
  119. Simard JF, Mittleman MA (2007) Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 34(3):469–473
  120. Jurgens MS, Jacobs JW, Geenen R et al (2013) Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Arthritis Care Res (Hoboken). doi: 10.1002/acr.21797
  121. Toms TE, Panoulas VF, Douglas KM et al (2008) Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. doi: 10.1186/ar2578
  122. Babadjanova G., Allolio B., Vollmer M., Reincke M., Schulte H. M., Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects, 10.1007/s002280050160
  123. Barcelona J. A. Sáez, Martín M. Carmona, López V. Navarro, Sancho J. J. Blanch, Tellaeche A. Puras, An open comparision of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg, 10.1007/s002280050603
  124. Fardet L, Feve B (2014) Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. doi: 10.1007/s40265-014-0282-9
  125. James Eric R., The Etiology of Steroid Cataract, 10.1089/jop.2006.0067
  126. Celojevic D, Carlsson T, Johansson B et al (2012) Cell adhesion molecule expression in human lens epithelial cells after corticosteroid exposure. Open Ophthalmol J. doi: 10.2174/1874364101206010042
  127. Chang JR, Koo E, Agron E et al (2011) Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology. doi: 10.1016/j.ophtha.2011.03.032
  128. Herbert J (2013) Cortisol and depression: three questions for psychiatry. Psychol Med. doi: 10.1017/S0033291712000955
  129. Matcham F, Rayner LF, Steer S et al (2013) The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). doi: 10.1093/rheumatology/ket169
  130. Matcham F, Norton S, Scott DL et al (2015) Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). doi: 10.1093/rheumatology/kev306
  131. Dinsen S, Baslund B, Klose M et al (2013) Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. doi: 10.1016/j.ejim.2013.05.014
  132. Fardet L, Nazareth I, Whitaker HJ et al (2013) Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. doi: 10.4088/JCP.12m08034
  133. Debono M, Ross RJ (2011) Optimal glucocorticoid therapy. Endocr Dev. doi: 10.1159/000321241
  134. Cutolo M, Iaccarino L, Doria A et al (2013) Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol 31(4):498–505
  135. Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-201067
  136. Emkey Ronald D., Lindsay Robert, Lyssy Jane, Weisberg Jerome S., Dempster David W., Shen Victor, The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis, 10.1002/art.1780390215
  137. Axelsen MB, Eshed I, Horslev-Petersen K et al (2015) A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204537
  138. Osamura Hiromi, PENETRATION OF TOPICAL CORTICOSTEROIDS THROUGH HUMAN EPIDERMIS, 10.1111/j.1346-8138.1982.tb02602.x
  139. VESTERGAARD P., REJNMARK L., MOSEKILDE L., Fracture risk associated with systemic and topical corticosteroids : CORTICOSTEROIDS AND FRACTURES, 10.1111/j.1365-2796.2005.01467.x
  140. Derendorf Hartmut, Möllmann Helmut, Grüner Alf, Haack Doris, Gyselby G, Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration, 10.1038/clpt.1986.45
  141. Derendorf H., Möllmann H., Barth J., Pharmakokinetik von intraartikulär applizierten Glukokortikoiden, 10.1055/s-2008-1047441
  142. Dernis E, Ruyssen-Witrand A, Mouterde G et al (2010) Use of glucocorticoids in rheumatoid arthritis—pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine. doi: 10.1016/j.jbspin.2009.12.010
  143. Yoon SH, Lee HY, Lee HJ et al (2013) Optimal dose of intra-articular corticosteroids for adhesive capsulitis: a randomized, triple-blind, placebo-controlled trial. Am J Sports Med. doi: 10.1177/0363546513480475
  144. Pereira RM, Freire de Carvalho CJ (2011) Glucocorticoid-induced myopathy. Joint Bone Spine. doi: 10.1016/j.jbspin.2010.02.025
  145. BUTTGEREIT F, BURMESTER G, LIPWORTH B, Optimised glucocorticoid therapy: the sharpening of an old spear, 10.1016/s0140-6736(05)71005-9
  146. van der Laan S, Meijer OC (2008) Pharmacology of glucocorticoids: beyond receptors. Eur J Pharmacol. doi: 10.1016/j.ejphar.2008.01.060
  147. De Bosscher K, Haegeman G, Elewaut D (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. doi: 10.1016/j.coph.2010.04.007
  148. Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet. doi: 10.1016/S0140-6736(09)60326-3
  149. Biddie SC, Conway-Campbell BL, Lightman SL (2012) Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatology (Oxford). doi: 10.1093/rheumatology/ker215
  150. Quax RA, Koper JW, de Jong PH et al (2012) In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis. Arthritis Res Ther. doi: 10.1186/ar4029
  151. Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol. doi: 10.1111/j.1476-5381.2010.01199.x
  152. van Oosten MJ, Dolhain RJ, Koper JW et al (2010) Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther. doi: 10.1186/ar3118
  153. Quax RA, Koper JW, Huisman AM et al (2015) Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int. doi: 10.1007/s00296-015-3235-z
  154. Sorrells Shawn F., Sapolsky Robert M., An inflammatory review of glucocorticoid actions in the CNS, 10.1016/j.bbi.2006.11.006
  155. Harbuz M., Is there a defect in cortisol production in rheumatoid arthritis?, 10.1093/rheumatology/38.4.298
  156. Cutolo M, Foppiani L, Minuto F (2002) Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest 25(10 Suppl):19–23
  157. Straub RH, Bijlsma JW, Masi A et al (2013) Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases–the 10-year update. Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2013.04.008
  158. Devogelaer Jean-Pierre, Goemaere Stefan, Boonen Steven, Body Jean-Jacques, Kaufman Jean-Marc, Reginster Jean-Yves, Rozenberg Serge, Boutsen Yves, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club, 10.1007/s00198-005-2032-z
  159. Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). doi: 10.1002/acr.20295
  160. Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. doi: 10.1056/NEJMcp1012926
  161. Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. doi: 10.1007/s00198-012-1958-1
  162. Hoes J N, Jacobs J W G, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy E H, Cutolo M, Da Silva J A P, Esselens G, Guillevin L, Hafstrom I, Kirwan J R, Rovensky J, Russell A, Saag K G, Svensson B, Westhovens R, Zeidler H, Bijlsma J W J, EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, 10.1136/ard.2007.072157
  163. Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-203249
  164. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. doi: 10.1007/s00198-012-2074-y
  165. Eastell Richard, Krege John H., Chen Peiqi, Glass Emmett V., Reginster Jean-Yves, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide, 10.1185/030079905x75096
  166. Arnson Y., Amital H., Shoenfeld Y., Vitamin D and autoimmunity: new aetiological and therapeutic considerations, 10.1136/ard.2007.069831
  167. Sans S., Kesteloot H., Kromhout D., , The burden of cardiovascular diseases mortality in Europe: Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe, 10.1093/oxfordjournals.eurheartj.a015434
  168. Solomon DH, Greenberg J, Curtis JR et al (2015) Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol. doi: 10.1002/art.39195
  169. van der Goes MC, Jacobs JW, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. doi: 10.1136/ard.2009.124958
  170. Fardet L (2013) Long term glucocorticoid therapy: so much remains to be done…. Rev Med Intern. doi: 10.1016/j.revmed.2013.02.017
  171. Clark Andrew R., Anti-inflammatory functions of glucocorticoid-induced genes, 10.1016/j.mce.2007.04.013